Eli Lilly is currently performing best and I added to my position during the recent market corrections.
The current P/E ratio for LLY is high however (54) whereas NOVO is just 12.
NOVO has about half a dozen weight loss drugs in the pipeline and still to come however, so I will also be looking to increase my holding in NOVO soon.
Note: This is not investment advice - please do your own research before investing. Drug company investing is a high risk - high reward adventure!
No comments:
Post a Comment